Exosomes for angiogenesis induction in ischemic disorders
© 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd..
Ischaemic disorders are leading causes of morbidity and mortality worldwide. While the current therapeutic approaches have improved life expectancy and quality of life, they are unable to "cure" ischemic diseases and instate regeneration of damaged tissues. Exosomes are a class of extracellular vesicles with an average size of 100-150 nm, secreted by many cell types and considered a potent factor of cells for paracrine effects. Since exosomes contain multiple bioactive components such as growth factors, molecular intermediates of different intracellular pathways, microRNAs and nucleic acids, they are considered as cell-free therapeutics. Besides, exosomes do not rise cell therapy concerns such as teratoma formation, alloreactivity and thrombotic events. In addition, exosomes are stored and utilized more convenient. Interestingly, exosomes could be an ideal complementary therapeutic tool for ischemic disorders. In this review, we discussed therapeutic functions of exosomes in ischemic disorders including angiogenesis induction through various mechanisms with specific attention to vascular endothelial growth factor pathway. Furthermore, different delivery routes of exosomes and different modification strategies including cell preconditioning, gene modification and bioconjugation, were highlighted. Finally, pre-clinical and clinical investigations in which exosomes were used were discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Journal of cellular and molecular medicine - 27(2023), 6 vom: 14. März, Seite 763-787 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moeinabadi-Bidgoli, Kasra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiogenesis |
|---|
| Anmerkungen: |
Date Completed 14.03.2023 Date Revised 02.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jcmm.17689 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352926783 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352926783 | ||
| 003 | DE-627 | ||
| 005 | 20231226054831.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jcmm.17689 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM352926783 | ||
| 035 | |a (NLM)36786037 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moeinabadi-Bidgoli, Kasra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exosomes for angiogenesis induction in ischemic disorders |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2023 | ||
| 500 | |a Date Revised 02.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. | ||
| 520 | |a Ischaemic disorders are leading causes of morbidity and mortality worldwide. While the current therapeutic approaches have improved life expectancy and quality of life, they are unable to "cure" ischemic diseases and instate regeneration of damaged tissues. Exosomes are a class of extracellular vesicles with an average size of 100-150 nm, secreted by many cell types and considered a potent factor of cells for paracrine effects. Since exosomes contain multiple bioactive components such as growth factors, molecular intermediates of different intracellular pathways, microRNAs and nucleic acids, they are considered as cell-free therapeutics. Besides, exosomes do not rise cell therapy concerns such as teratoma formation, alloreactivity and thrombotic events. In addition, exosomes are stored and utilized more convenient. Interestingly, exosomes could be an ideal complementary therapeutic tool for ischemic disorders. In this review, we discussed therapeutic functions of exosomes in ischemic disorders including angiogenesis induction through various mechanisms with specific attention to vascular endothelial growth factor pathway. Furthermore, different delivery routes of exosomes and different modification strategies including cell preconditioning, gene modification and bioconjugation, were highlighted. Finally, pre-clinical and clinical investigations in which exosomes were used were discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a angiogenesis | |
| 650 | 4 | |a exosomes | |
| 650 | 4 | |a hypoxia | |
| 650 | 4 | |a microRNA | |
| 650 | 4 | |a physiology | |
| 650 | 4 | |a regenerative medicine | |
| 650 | 4 | |a stem cells | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 700 | 1 | |a Rezaee, Malihe |e verfasserin |4 aut | |
| 700 | 1 | |a Hossein-Khannazer, Nikoo |e verfasserin |4 aut | |
| 700 | 1 | |a Babajani, Amirhesam |e verfasserin |4 aut | |
| 700 | 1 | |a Aghdaei, Hamid Asadzadeh |e verfasserin |4 aut | |
| 700 | 1 | |a Arki, Mandana Kazem |e verfasserin |4 aut | |
| 700 | 1 | |a Afaghi, Siamak |e verfasserin |4 aut | |
| 700 | 1 | |a Niknejad, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Vosough, Massoud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cellular and molecular medicine |d 2000 |g 27(2023), 6 vom: 14. März, Seite 763-787 |w (DE-627)NLM118801236 |x 1582-4934 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:6 |g day:14 |g month:03 |g pages:763-787 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jcmm.17689 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 6 |b 14 |c 03 |h 763-787 | ||